Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned a consensus rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $21.57.

Several research firms recently weighed in on ZVRA. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Cantor Fitzgerald began coverage on shares of Zevra Therapeutics in a research report on Wednesday, January 8th. They set an “overweight” rating and a $25.00 price objective on the stock. Finally, Guggenheim began coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 target price for the company.

Zevra Therapeutics Price Performance

ZVRA opened at $8.04 on Tuesday. The stock has a 50-day moving average price of $8.63 and a 200-day moving average price of $7.88. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The stock has a market capitalization of $429.18 million, a P/E ratio of -4.08 and a beta of 2.01. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the firm posted ($0.40) EPS. Equities analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its position in shares of Zevra Therapeutics by 17.9% during the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after buying an additional 8,619 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Zevra Therapeutics in the 2nd quarter worth approximately $474,000. SG Americas Securities LLC acquired a new position in shares of Zevra Therapeutics in the third quarter worth about $105,000. Finally, City State Bank grew its holdings in Zevra Therapeutics by 14.1% in the third quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.